A Study of LY4257496 in Participants With Cancer (OMNIRAY)
← catalyst calendarNCT07114601 · readout ≤ 1,349 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
421estimated
Sites
32
Countries
Canada, China, France +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-06 | actual | When the study began enrolling |
| Primary completion | Apr 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2035 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Neoplasms
- Colorectal Neoplasms
- Prostate Neoplasm
- Endometrial Neoplasms
- Neoplasm Metastasis
- Stomach Neoplasms
- Esophageal Neoplasms
Interventions
- Drug: LY4257496
- Drug: Standard of Care Anticancer Therapies
- Diagnostic test: LY4257529
Primary outcomes
what the primary-completion date above is the date OFPhase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496
measured From Cycle 1 Day 1 (C1D1) through 28 days after the first dose of study drug. Cycle = 28 days
Phase 1a Dose Optimization: Number of Dose Limiting Toxicities of LY4257496
measured From Cycle 1 Day 1 (C1D1) through 28 days after the first dose of study drug. Cycle = 28 days
Phase 1b Dose Expansion and Optimization: Objective Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)
measured From C1D1 through efficacy follow-up, estimated as Week 42. Cycle = 42 weeks
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed